{
  "docId": "019dd923-5ca1-7489-b636-bc879d1b6d64",
  "docSlug": "17680cec2cbd3510",
  "documentTitle": "Accelerated Access Review UK Mapping",
  "authorId": "Deloitte",
  "authorName": "Deloitte",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 90,
  "pageCount": 109,
  "prevPage": 89,
  "nextPage": 91,
  "slideType": "pain_points",
  "function": "diagnose",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "LHE = Local Health Economy; TAP = Technology Appraisal Programme",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b636-bc879d1b6d64/90",
  "deckHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64#slide-90",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.06,
        "y": 0.71
      },
      "kind": "list",
      "text": "Majority of interviewed NHS stakeholders believed that local commissioning and adoption is the greatest barrier to access. Major barriers to clinician use of in vitro diagnostics are financial: Speed of pricing and contracting update (e.g., inclusion on Tariff) even for NICE-recommended products. Departmental and LHE budget silos and horizons limit the uptake of products, especially where benefits will accrue across multiple care pathways and settings of care. Double running costs when changes occur.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0048ef0e-1be8-4cb1-8688-e0db183da85e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.51,
        "y": 0.29
      },
      "kind": "list",
      "text": "Agreement among interviewed stakeholders that adoption, especially at local level is complex and slow. Lack of a clear route to market identified as a problem. Acceptance that lack of funding mandate for most NICE-recommended in vitro diagnostic limits local commissioner willingness to pay for innovative in vitro diagnostics. Feeling that lack of central coordination results in significant duplication across CCGs and / or providers. Sense that commercialisation capability is a problem, especially for SMEs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4982e620-846d-4e01-b9cf-6b2f9a88d9af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.43,
        "x": 0.51,
        "y": 0.67
      },
      "kind": "list",
      "text": "Feeling that NHS commissioners do not focus enough on patients and their quality of life, and spend too much time meeting minimum performance standards and financing constraints. Feel that some inequalities between LHEs are due to variation in the adoption of innovative medtech. Specific diseases could be used as a 'test-bed' for reform from development through to adoption.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6710940-6f93-4d48-9dec-51ab9abde595",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.06,
        "y": 0.29
      },
      "kind": "list",
      "text": "Industry stakeholders interviewed are strongly of the opinion that local commissioning and adoption of medtech is the greatest barrier to patient access. No clear route to market, with high variability between LHEs and access highly dependent on clinician relationships. Lack of funding mandate for non-TAP NICE-assessed products limits adoption. Feeling that in vitro diagnostics are just considered a system overhead cost by commissioners. Little contract standardisation, which particularly affects SMEs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e09ef67f-342c-4871-8e2a-bbb5459bea55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Notes: LHE = Local Health Economy; TAP = Technology Appraisal Programme\nSource: Stakeholder interviews, workshops and Deloitte analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "030c6d3c-0667-4664-b4fc-32c7459ddac8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.38,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Stakeholder Views",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd532726-e40e-4063-acc7-c90f93bf9000",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b34b6547-9eb4-4e44-b2ce-20856ea54eae",
      "evidence": "list/bullet: Agreement among interviewed stakeholders that adoption, especially at local level is complex and slow. Lack of a clear route to market identified as a problem. Acceptance that lack of funding mandate for mos",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 109,
      "from": 21,
      "beatId": "4bae8ed9-97e4-4ca8-988f-171e64b0598d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 109,
      "from": 21,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "575c67ea-abbb-4bd3-80bc-943f97973ed4",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 1,
      "objective": "How can the NHS improve access to medical innovations?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}